| Delaware (State or other jurisdiction of incorporation or organization) | | | 26-3687168 (I.R.S. Employer Identification | |
| Large accelerated filer ☐ | | | Accelerated filer ☐ | |
| Non-accelerated filer ☒ | | | Smaller reporting company ☒ | |
| | | | Emerging growth company ☐ | |
| | ||||||||||||||||||||||||||||
Title of Each Class of Securities to be Registered | | | | Amount to be Registered(1) | | | | Offering Price Per Share(2) | | | | Proposed Maximum Aggregate Offering Price(2) | | | | Amount of Registration Fee | | ||||||||||||
Common Stock, $0.001 par value | | | | | | 92,399,805 | | | | | | $ | 2.69 | | | | | | $ | 248,555,475.45 | | | | | | $ | 27,117.41 | | |
| ||||||||
| | | | 1 | | | ||
| | | | | 2 | | | |
| | | | | 2 | | | |
| | | | | 3 | | | |
| | | | | 4 | | | |
| | | | | 5 | | | |
| | | | | 6 | | | |
| | | | | 7 | | | |
| | | | | | | ||
| | | | | 18 | | | |
| | | | | 19 | | | |
| | | | | 20 | | | |
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | |
| | | Shares Beneficially Owned Before Offering(2) | | | Shares Offered | | | Shares Beneficially Owned After Offering(3) | | |||||||||||||||
Selling Stockholder(1) | | | Number | | | Percent | | ||||||||||||||||||
Lazarus Life Sciences I, LLC(4) | | | | | 8,777,373 | | | | | | 8,777,373 | | | | | | — | | | | | | * | | |
Entities affiliated with Perceptive(5) | | | | | 37,704,551 | | | | | | 37,704,551 | | | | | | — | | | | | | * | | |
Entities affiliated with Xontogeny(6) | | | | | 8,777,373 | | | | | | 8,777,373 | | | | | | — | | | | | | * | | |
Entities affiliated with Fairmount(7) | | | | | 4,092,166 | | | | | | 4,092,166 | | | | | | — | | | | | | * | | |
Xencor, Inc.(8) | | | | | 4,187,206 | | | | | | 4,187,206 | | | | | | — | | | | | | * | | |
RA Capital Healthcare Fund, L.P.(9) | | | | | 5,174,000 | | | | | | 5,174,000 | | | | | | — | | | | | | * | | |
Entities affiliated with Cormorant(10) | | | | | 4,526,000 | | | | | | 4,526,000 | | | | | | — | | | | | | * | | |
Logos Global Master Fund LP(11) | | | | | 3,234,000 | | | | | | 3,234,000 | | | | | | — | | | | | | * | | |
Entities affiliated with Venrock(12) | | | | | 3,234,000 | | | | | | 3,234,000 | | | | | | — | | | | | | * | | |
Entities affiliated with Boxer Capital(13) | | | | | 1,940,000 | | | | | | 1,940,000 | | | | | | | | | | | | * | | |
Acorn Bioventures, L.P.(14) | | | | | 1,617,000 | | | | | | 1,617,000 | | | | | | — | | | | | | * | | |
Commodore Capital Master LP(15) | | | | | 1,617,000 | | | | | | 1,617,000 | | | | | | — | | | | | | * | | |
Citadel Multi-Strategy Equities Master Fund Ltd.(16) | | | | | 1,294,000 | | | | | | 1,294,000 | | | | | | — | | | | | | * | | |
Entities affiliated with Acuta(17) | | | | | 1,896,0000 | | | | | | 1,294,000 | | | | | | 602,000 | | | | | | 2.4% | | |
Sphera Biotech Master Fund, LP(18) | | | | | 1,294,000 | | | | | | 1,294,000 | | | | | | — | | | | | | * | | |
Wedbush Healthcare Partners 2021 Fund, LLC(19) | | | | | 404,000 | | | | | | 404,000 | | | | | | — | | | | | | * | | |
Serrado Opportunity Fund LLC(20) | | | | | 243,000 | | | | | | 243,000 | | | | | | — | | | | | | * | | |
Viridian, LLC(21) | | | | | 2,990,136 | | | | | | 2,990,136 | | | | | | — | | | | | | * | | |
| SEC registration fee. | | | | $ | 27,550 | | |
| FINRA filing fee | | | | $ | (1) | | |
| Printing and engraving | | | | $ | (1) | | |
| Accounting services | | | | $ | (1) | | |
| Legal fees of registrant’s counsel. | | | | $ | (1) | | |
| Miscellaneous | | | | $ | (1) | | |
| Total | | | | $ | (1) | | |
| Registration Fee – Securities and Exchange Commission | | | | $ | 27,117 | | |
| Accountants Fees and Expenses | | | | $ | 5,000 | | |
| Legal Fees and Expenses | | | | $ | 100,000 | | |
| Miscellaneous | | | | $ | 5,000 | | |
| Total | | | | $ | 137,117 | | |
| Exhibit No. | | | Description | |
| 1* | | | Form of Underwriting Agreement | |
| 4.1 | | | Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K (File No. 001-37467) filed with the SEC on September 8, 2021) | |
| 4.2 | | | Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.3 to the Registrant’s Current Report on Form 8-K (File No. 001-37467) filed with the SEC on September 8, 2021) | |
| 4.3* | | | Form of Deposit Agreement | |
| 4.4* | | | Form of Warrant Agreement | |
| 4.5* | | | Form of Unit Agreement | |
| 5.1 | | | | |
| 23.1 | | | | |
| 23.2 | | | | |
| 24 | | | | |
| 107 | | | |
| Signature | | | Title | | | Date | |
| /s/ Jill C. Milne | | | President and Chief Executive Officer and Director | | | | |
| /s/ Noah Clauser | | | Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) | | | | |
| Kenneth Bate | | | | | | ||
| Joanne | | | Director | | | | |
| | | | Director | | | | |
| Hugh | | | Director | | | |
| Signature | | | Title | | | Date | |
| Michael Kishbauch | | | Director | | | May 11, 2023 | |
| /s/ GREGG LAPOINTE Gregg Lapointe | | | Director | | | | |
| ||||||||
Jonathan Violin | | | Director | | | |||
|